The discovery that patients with mutant IDH1/2 GBM have a better outcome compared to those with wild-type enzymes has spurred robust research to study the consequences of IDH mutations on cellular metabolism and to design new effective targeted molecular therapies. This evidence concerns the gene IDH2 and glioblastoma.